Terrance Kummer

Assistant Professor of Neurology; Division of Neurocritical Care

Washington University in Saint Louis School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Terrance Kummer is an Assistant Professor of Neurology in the Division of Neurocritical Care at Washington University School of Medicine in St. Louis, USA. His research areas include the effects of vagus nerve stimulation on cardiovascular function in subarachnoid hemorrhage patients and the role of CNIH3 in spatial memory and synaptic plasticity. He has also contributed to studies on synaptotoxic activities in Alzheimer’s disease and methods for localizing focal brain injury using EEG.

Articles (7)

Background: Subarachnoid hemorrhage (SAH) is characterized by intense central inflammation, leading to substantial post-hemorrhagic complications such as vasospasm and delayed cerebral ischemia. Given the anti-inflammatory effect of transcutaneous auricular vagus nerve stimulation (taVNS) and its ability to promote brain plasticity, taVNS has emerged as a promising therapeutic option for SAH patients. However, the effects of taVNS on cardiovascular dynamics in critically ill patients, like those with SAH, have not yet been investigated. Given the association between cardiac complications and elevated risk of poor clinical outcomes after SAH, it is essential to characterize the cardiovascular effects of taVNS to ensure this approach is safe in this fragile population. Therefore, this study assessed the impact of both acute and repetitive taVNS on cardiovascular function. Methods: In this randomized clinical trial, 24 SAH patients were assigned to either a taVNS treatment or a sham treatment group. During their stay in the intensive care unit, we monitored patient electrocardiogram readings and vital signs. We compared long-term changes in heart rate, heart rate variability (HRV), QT interval, and blood pressure between the two groups. Additionally, we assessed the effects of acute taVNS by comparing cardiovascular metrics before, during, and after the intervention. We also explored acute cardiovascular biomarkers in patients exhibiting clinical improvement. Results: We found that repetitive taVNS did not significantly alter heart rate, QT interval, blood pressure, or intracranial pressure (ICP). However, repetitive taVNS increased overall HRV and parasympathetic activity compared to the sham treatment. The increase in parasympathetic activity was most pronounced from 2 to 4 days after initial treatment (Cohen’s d = 0.50). Acutely, taVNS increased heart rate, blood pressure, and peripheral perfusion index without affecting the corrected QT interval, ICP, or HRV. The acute post-treatment elevation in heart rate was more pronounced in patients who experienced a decrease of more than one point in their modified Rankin Score at the time of discharge. Conclusions: Our study found that taVNS treatment did not induce adverse cardiovascular effects, such as bradycardia or QT prolongation, supporting its development as a safe immunomodulatory treatment approach for SAH patients. The observed acute increase in heart rate after taVNS treatment may serve as a biomarker for SAH patients who could derive greater benefit from this treatment. Funding: The American Association of Neurological Surgeons (ALH), The Aneurysm and AVM Foundation (ALH), The National Institutes of Health R01-EB026439, P41-EB018783, U24-NS109103, R21-NS128307 (ECL, PB), McDonnell Center for Systems Neuroscience (ECL, PB), and Fondazione Neurone (PB). Clinical trial number: NCT04557618 .

Year:

2025

Background: Subarachnoid hemorrhage (SAH) is characterized by intense central inflammation, leading to substantial post-hemorrhagic complications such as vasospasm and delayed cerebral ischemia. Given the anti-inflammatory effect of transcutaneous auricular vagus nerve stimulation (taVNS) and its ability to promote brain plasticity, taVNS has emerged as a promising therapeutic option for SAH patients. However, the effects of taVNS on cardiovascular dynamics in critically ill patients, like those with SAH, have not yet been investigated. Given the association between cardiac complications and elevated risk of poor clinical outcomes after SAH, it is essential to characterize the cardiovascular effects of taVNS to ensure this approach is safe in this fragile population. Therefore, this study assessed the impact of both acute and repetitive taVNS on cardiovascular function. Methods: In this randomized clinical trial, 24 SAH patients were assigned to either a taVNS treatment or a sham treatment group. During their stay in the intensive care unit, we monitored patient electrocardiogram readings and vital signs. We compared long-term changes in heart rate, heart rate variability (HRV), QT interval, and blood pressure between the two groups. Additionally, we assessed the effects of acute taVNS by comparing cardiovascular metrics before, during, and after the intervention. We also explored acute cardiovascular biomarkers in patients exhibiting clinical improvement. Results: We found that repetitive taVNS did not significantly alter heart rate, QT interval, blood pressure, or intracranial pressure (ICP). However, repetitive taVNS increased overall HRV and parasympathetic activity compared to the sham treatment. The increase in parasympathetic activity was most pronounced from 2 to 4 days after initial treatment (Cohen’s d = 0.50). Acutely, taVNS increased heart rate, blood pressure, and peripheral perfusion index without affecting the corrected QT interval, ICP, or HRV. The acute post-treatment elevation in heart rate was more pronounced in patients who experienced a decrease of more than one point in their modified Rankin Score at the time of discharge. Conclusions: Our study found that taVNS treatment did not induce adverse cardiovascular effects, such as bradycardia or QT prolongation, supporting its development as a safe immunomodulatory treatment approach for SAH patients. The observed acute increase in heart rate after taVNS treatment may serve as a biomarker for SAH patients who could derive greater benefit from this treatment. Funding: The American Association of Neurological Surgeons (ALH), The Aneurysm and AVM Foundation (ALH), The National Institutes of Health R01-EB026439, P41-EB018783, U24-NS109103, R21-NS128307 (ECL, PB), McDonnell Center for Systems Neuroscience (ECL, PB), and Fondazione Neurone (PB). Clinical trial number: NCT04557618 .

Year:

2025

Traumatic brain injury (TBI) disrupts white matter tracts essential for cognition and emotion. Diffusion tensor imaging (DTI) can noninvasively measure white matter integrity. However, DTI has been inconsistent in predicting patient recovery from TBI, possibly due to the complex, dynamic, and individual-specific process of post-TBI white matter remodeling. Here, we employed dense longitudinal neuroimaging to track white matter recovery weekly over six months after a TBI within a single patient and a control in a similar age group (21 vs. 24 y.o.). In the patient, but not in the control, DTI metrics precisely tracked parabolic trajectories across time, with early structural alterations continuing for more than 15 weeks before reversing direction. The extent of alteration in each tract was correlated with the time until reversal. These continuous DTI changes also mediated recovery of cognitive and emotional function, suggesting they are not passive markers of damage but dynamic processes underlying functional improvement. Complementary diffusion basis spectrum imaging (DBSI) revealed an initial phase of cellular loss followed by inflammatory remodeling, vascular adaptations, and persistent metabolic activity. Our findings indicate that recovery does not follow predefined phases but rather individualized transition points, which could define optimal windows for rehabilitation. Identifying these inflection points may enable personalized interventions aligned with biologically relevant structural shifts, rather than broad recovery periods.

Year:

2025

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Evan Gordon

Assistant Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Sina Khanmohammadi

Assistant Professor

University of Oklahoma

UNITED STATES
View details

Deanna M Barch

Chair, Department of Psychological & Brain Sciences/Professor of Psychological & Brain Sciences, Psychiatry, and Radiology

Washington University in St. Louis

UNITED STATES
View details